Tr1X is a private, clinical-stage biotechnology company focused on developing a novel class of regulatory T cell-based products to cure autoimmune and inflammatory diseases. Founded by industry experts, including the scientists who discovered Type 1 regulatory T (Tr1) cells, the company is developing a pipeline of off-the-shelf allogeneic cell therapies for autoimmune diseases with high unmet medical need. Our TRX cells are designed to mimic the function of naturally occurring Tr1 cells, which work to restore immune tolerance, stopping severe autoimmune and inflammatory disease in its tracks. Tr1X is the first company ever to use an allogeneic engineered Tr1 cell therapy in clinical trials. Tr1X is headquartered in San Diego, CA. For more information, please visit www.tr1x.bio.
Company Details
- Employees
- 39
- Address
- 9310 Athena Circle,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.tr1x.bio
- Keywords
- immunology, immunotherapy, cell therapy, genetic engineering, biotechnology, autoimmune disease, inflammatory disease, research, T cells, tolerance.
- HQ
- San Diego, California
Tr1x Questions
Tr1X's website is https://www.tr1x.bio
Tr1X's LinkedIn profile is https://www.linkedin.com/company/tr1x
Tr1X has
39 employees.
View email and phone details for 39
employees at Tr1X.
Tr1X's industry is
Biotechnology Research
Tr1X's categories are Biotechnology Research
